304 related articles for article (PubMed ID: 25763785)
1. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
2. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.
Chao C; Leyden WA; Xu L; Horberg MA; Klein D; Towner WJ; Quesenberry CP; Abrams DI; Silverberg MJ
AIDS; 2012 Nov; 26(17):2223-31. PubMed ID: 22951631
[TBL] [Abstract][Full Text] [Related]
3. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Krishnan S; Schouten JT; Jacobson DL; Benson CA; Collier AC; Koletar SL; Santana J; Sattler FR; Mitsuyasu R;
Oncology; 2011; 80(1-2):42-9. PubMed ID: 21606663
[TBL] [Abstract][Full Text] [Related]
4. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E; Kirk O; Furrer H; De Wit S; Phillips A; Lundgren JD; Sabin CA;
BMC Infect Dis; 2013 Oct; 13():471. PubMed ID: 24106926
[TBL] [Abstract][Full Text] [Related]
5. Cancer in HIV-infected persons from the Caribbean, Central and South America.
Fink VI; Shepherd BE; Cesar C; Krolewiecki A; Wehbe F; Cortés CP; Crabtree-Ramírez B; Padgett D; Shafaee M; Schechter M; Gotuzzo E; Bacon M; McGowan C; Cahn P; Masys D;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):467-73. PubMed ID: 21239992
[TBL] [Abstract][Full Text] [Related]
6. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
[TBL] [Abstract][Full Text] [Related]
7. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
8. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
9. Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial.
Jespersen S; Hønge BL; Krarup H; Medstrand P; Sørensen A; Medina C; Té DDS; Correira FG; Erikstrup C; Østergaard L; Wejse C; Laursen AL;
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):386-393. PubMed ID: 30044302
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
11. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
12. Class of antiretroviral drugs and the risk of myocardial infarction.
; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
[TBL] [Abstract][Full Text] [Related]
14. HIV infection and the risk of cancers with and without a known infectious cause.
Silverberg MJ; Chao C; Leyden WA; Xu L; Tang B; Horberg MA; Klein D; Quesenberry CP; Towner WJ; Abrams DI
AIDS; 2009 Nov; 23(17):2337-45. PubMed ID: 19741479
[TBL] [Abstract][Full Text] [Related]
15. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.
Long JL; Engels EA; Moore RD; Gebo KA
AIDS; 2008 Feb; 22(4):489-96. PubMed ID: 18301061
[TBL] [Abstract][Full Text] [Related]
18. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Furrer H; Telenti A; Hirschel B; Vernazza PL; Bernasconi E; Rickenbach M; Perrin L; Ledergerber B; Günthard HF;
Arch Intern Med; 2007 Sep; 167(16):1782-90. PubMed ID: 17846398
[TBL] [Abstract][Full Text] [Related]
19. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.
Sankatsing RR; Wit FW; Vogel M; de Groot E; Brinkman K; Rockstroh JK; Kastelein JJ; Stroes ES; Reiss P
Atherosclerosis; 2009 Feb; 202(2):589-95. PubMed ID: 18599064
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
